A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

Condition(s) studied

Investigational drug(s) / intervention(s)

ASKG915: ASKG915 is administered intravenously at a scheduled dose. The drug was given once every 3 weeks or 4 weeks for a cycle.

Paclitaxel + Bevacizumab: Paclitaxel is administered intravenously at a dose of 80 mg/m², once weekly on a 21-day cycle. Bevacizumab is administered intravenously at dose of 15mg/kg, once every 3 weeks on a 21-day cycle.

Fruquintinib: The recommended dose of Fruquintinib is 5 mg orally once daily, with or without food for the first 21 days of each 28-day cycle.

Docetaxel: Docetaxel is administered intravenously at 75 mg/m², once every 3 weeks on a 21-day cycle.

Study summary

The study is a dose-escalation and dose-expansion study to evaluate the safety, tolerability, and pharmacokinetics of ASKG915 as a single agent or in combination with standard of care (SOC) in patients with selected types of advanced solid tumors.

Eligibility

Primary outcome measure(s)

• Dose limiting toxicities (DLTs) — 21days or 28 days
  To evaluate the safery of ASKG915 in subjects.
• Adverse events(AEs) — From the first dose to 30 days after the last dose
  To evaluate the safery of ASKG915 in subjects.

Trial sites (4)

Other trials for the same condition